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Background: Infection risks among people who inject drugs (PWID) are widely recognised, 
but few studies have focused on image and performance enhancing drugs (IPEDs). Globally, 
concern about IPED injection has increased and, in the United Kingdom, IPEDs injectors 
have become the largest group using Needle and Syringe Programmes. Blood borne virus 
(BBV) prevalence trends among IPED injectors are explored. 
Method: Data from two surveys of IPED injectors (2010-11; 2012-13) and the national bio-
behavioural surveillance system for PWID (1992-97; 1998-2003; 2004-09) were merged. 
Psychoactive drug injectors and women were excluded. Logistic regression analyses 
explored temporal changes. 
Results: Between 1992 and 2009, median age increased from 25 to 29 years (N=1,296), 
years injecting from 2 to 4. There were 53 men who had sex with men (MSM). Overall, 
0.93% had HIV, 4.4% ever had hepatitis B (HBV), and 3.9% hepatitis C (HCV, from 1998, 
N=1,083). In multivariable analyses, HIV increased in 2004-09 (adjusted Odds Ratio 
(AOR)=10 [95%CI 0.94-106] vs. 1992-2003), and remained elevated (AOR=4.12, 95%CI 
0.31-54, 2012-13); HBV also increased in 2004-09 (AOR=3.98, 95%CI 1.59-9.97). HCV 
prevalence increase was only borderline significant (AOR=2.47, 95%CI 0.90-6.77, 2010-11). 
HIV and HBV were associated with MSM, and HCV with sharing needles/syringes. Uptake of 
diagnostic testing for HIV and HCV, and HBV vaccination increased (to 43%, 32% and 44% 
respectively). Condom use was consistently poor; needle/syringe sharing occurred. 
Conclusion: BBV prevalences among IPEDs injectors have increased, and for HIV is now 
similar to that among psychoactive drug injectors. Targeted interventions to reduce risks are 
indicated. 
 
Keywords:  
HIV, Hepatitis B, Hepatitis C, people who inject drugs, behaviours, image and performance 
enhancing drugs.
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Introduction 
It is widely recognised that people who inject drugs (PWID) are vulnerable to blood-borne 
viral (BBV) infections. However, whilst BBVs have been extensively studied among 
individuals who inject psychoactive drugs (such as opiates and stimulants)1,2,3 few studies 
have focused on those who inject image and performance enhancing drugs (IPEDs).4,5,6,7 A 
wide range of illicit drugs can be injected with the aim of altering body image and/or 
performance. These drugs range from human growth hormone8, a range of peptide 
hormones,9,10 the most commonly injected IPEDs anabolic androgenic steroids3,11, to tanning 
drugs, such as ‘Melanotan II’.12  
Globally there is increasing concern about the extent and public health consequences of 
IPED use,4,11,13 and recently a number of studies have raised concerns about infections, 
including HIV, among those who inject IPEDs.6,7 In particular, there has been concern that 
HIV and hepatitis B virus (HBV) infections might have increased over time among this group 
in the United Kingdom (UK).7 This has occurred during a time when the number of people 
who inject IPEDs in contact with needle and syringe programmes (NSPs) has grown in the 
UK14 and Australia.15 
Infection risks for BBVs among IPED injectors are, for a number of reasons, likely to be 
different to those among people injecting psychoactive drugs. Firstly, users’ behaviours, and 
so risks of infection, can be impacted by the effects of psychoactive drugs, with the use of 
these leading to disinhibition and compulsive usage.16 Although there is increasing evidence 
to support some levels of dependence amongst IPED users and for these drugs having 
hedonic effects.17,18,19 Secondly, there are differences in injecting practice, as IPEDs are 
injected only subcutaneously or intramuscularly and usually require much less preparation 
than psychoactive drugs.3,7,14 Finally, IPEDs are typically injected less frequently than 
psychoactive drugs and their use can be cyclical.4,7,14 These differences have been thought 
to place those who inject IPEDs at a much lower risk of injection-related infections than those 
who inject psychoactive drugs.4,14 However, studies suggest that those using IPEDs may 
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have greater sexual risks as they commonly report risky sexual behaviours4,7,20,21 and low 
levels of condom use.7,20,22 
In response to the increasing concerns about IPED use and the possible increase in the 
prevalence of BBVs among this population, data from a number of related sero-behavioural 
surveys were used to examine temporal changes in the UK. The aim of this study was to 
describe changes between 1992 and 2012 in:- a) injecting risk; b) sexual behaviours; and c) 
BBV prevalence among people injecting IPEDs.   
 
Methods 
Data from cross-sectional sero-behavioural studies were extracted and analysed. 
Surveys 
In England and Wales, PWID have been recruited into a voluntary unlinked-anonymous 
monitoring (UAM) survey since 1990; methodological details of which have been published 
previously.23,24 Briefly, agencies providing services to PWID (e.g. NSPs and addiction 
services) at sentinel locations invite clients who have ever injected drugs to participate. 
Sentinel sites are selected so as to reflect both the geographic distribution and range of 
services offered to PWID. Those who consent to participate provide a biological sample and 
self-complete a brief questionnaire. This survey has multi-site ethics approval. 
From 1990-2009 this survey had a single questionnaire focused on psychoactive drug use 
and collected oral fluid samples. During 2010, the biological sample was changed to a dried 
blood spot (DBS) and the questionnaire was reviewed. At the same time a UAM sub-survey 
focused on IPED use was implemented, in response to the increased concerns about risk in 
this group.14 The initial IPED sub-survey during 2010-11 collected oral fluid samples and 
used a modified questionnaire focused on IPED use.7 Following this initial sub-survey, a 
routine biennial IPED sub-survey was established using a similar questionnaire, but 
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collecting DBS samples. The first wave of this routine survey was undertaken during 2012-
13.25  
The samples collected in the surveys were tested for antibodies to HIV (anti-HIV), hepatitis B 
core antigen (anti-HBc) and hepatitis C virus (anti-HCV), using previously published methods 
by the same laboratory.7,26,27 Common data items were extracted from the main UAM Survey 
and the two sub-surveys for male participants who reported injecting only IPEDs during the 
preceding year. The main UAM Survey had collected limited data on the drugs used prior to 
1992 and, because of the small number of IPED users recruited into this survey annually, 
three six-year time periods (1992-1997, 1998-2003, 2004-2009) were used. When combining 
data from six survey years into a single time period only an individual’s first participation 
during that period was included (self-reported previous participations were used to exclude 
repeats). Data analysed were thus for five time periods; three from the main UAM Survey 
(1992-1997, 1998-2003, 2004-2009) plus the two IPED sub-surveys (2010-2011, 2012-
2013). 
Risk factors from the questionnaire data were analysed in categorical form for the most part, 
either based on yes/no responses or pre-defined categories in the questionnaire, or groups 
in the case of continuous variables. The latter were chosen to provide roughly equal size 
groups with a sufficient number in each. Factors of interest included the five time periods, 
region (Southern and Eastern England; the Midlands [England]; Northern England; Wales), 
age (<25, 25-34, 35+ years), injecting duration (<2, 2-5, >5 years), UK born, ever received a 
used needle/syringe, ever used a NSP, HBV vaccination uptake, number of sexual partners 
(preceding year; none, 1, 2-9, 10+), condom use (always, sometimes, never), sexuality (men 
who have sex with men [MSM]), and ever tested for HCV or HIV. 
Statistical methods 
Changes in risk factors over time were assessed via chi-squared tests with survey period for 
categorical variables; and for some continuous variables, the association with time was 
measured via Pearson’s correlation coefficient. Risk factors for BBV infection (HCV, HBV 
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and HIV) were analysed via logistic regression. Tests for HCV and HBV had reduced 
sensitivity prior to the introduction of DBS; we used a routine based on the expectation-
maximisation algorithm to account for imperfect sensitivity and specificity28 implemented via 
the Stata command logitem. Although we examined the relationship between past 
diagnostic testing for HIV/HCV and HBV vaccination with infection status, these variables 
were not included in multivariable analysis as there is not a causal relationship between 
previous testing and infection status, nor for HBV vaccination and HCV/HIV status; i.e., these 
variables may show an association due to higher uptake in high-risk individuals, but the 
test/vaccine does not in itself change the risk of infection. 
As there was a substantial proportion of missing data for some variables, a multiple 
imputation approach was employed in the primary analysis. Missing data can lead to a loss 
of power, but more significantly, informatively missing data may lead to biased results in 
complete case analyses, where only observations with no missing data are analysed.29 We 
used the approach of chained equations, which produces multiple datasets of predicted 
values based on the relationships between variables, and combines the results to account for 
uncertainty in predictions according to Rubin’s rules30 (see Appendix A, Supplemental Digital 
Content, http://links.lww.com/QAI/A747). 
Due to the small number of observed infections, it was desirable to find a parsimonious 
model to describe the data. As the number of potential covariates was not large, a complete 
search of all possible models was undertaken for each infection, and the Akaike information 
criteria (AIC) used for comparisons.31 Time-period was included in all models, as trends over 
time are of principal interest. AC
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Results 
Descriptive statistics 
In total, 1,296 participations were included in the analyses, with 611 (47%) from 2010 
onwards and the fewest during 2004-2009 (129, 10%). Figure 1 and Table 1 show 
distributions of participant characteristics over time. The age and injecting duration of those 
sampled increased (p<0.001 for both), with a median injecting duration of two years (IQR 0-
4) in 1992-1997 and four years (IQR 1-10) in 2012-2013; and a median age of 25 years (IQR 
22-29) in 1992-1997 and 29 years (IQR 23-35) in 2012-2013. Condom use showed no 
significant change over time (p=0.355); overall only 20.5% reporting always using a condom, 
with 39.5% sometimes doing so, and 40% never. Significant differences in reported number 
of sexual partners during the preceding year was observed over time (p=0.012) although this 
did not show any overall trend. Overall, 6.8% reported no partners, 42% one, 42% 2-9 and 
9.9% ten or more.  
Other behavioural and demographic variables showed some changes over time; ever used 
NSP varied between 78-90%. Reporting ever receiving used needles/syringes increased 
from 13% in 1992-1997 to 34.5% in 1998-2003 and 40% in 2004-2009 before dropping to 
less than 6% from 2010; this drop might be related to the move to the IPED focused 
questionnaire in 2010 even though questions were similar. Vaccination for HBV and testing 
for HCV and HIV increased between 1998-2003 and 2004-2009, and stayed roughly stable 
thereafter. The proportion born in the UK and MSM have both remained stable over time, 
with 712/746 (95%) UK-born overall (data collected from 2004 only) and 53 (4.1%) MSM. 
In total 42/1083 (3.9%) participations tested positive for anti-HCV; 57/1296 (4.4%) for anti-
HBc; and 12/1296 (0.93%) for anti-HIV. Figure 2 shows prevalence of these three infections 
over time. Prevalence rose sharply for all three infections in the 2004-2009 period, but fell 
again in 2010-2011 and 2012-2013. 
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Patterns of missing data 
Injecting duration had the largest amount of missing data (mainly due to age first injected 
being missing); most of the other variables contained relatively small amounts (<5%) of 
missing data and a number of data items (e.g. UK born) were not collected in earlier survey 
years and so were missing for these (see Appendix A, Supplemental Digital Content, 
http://links.lww.com/QAI/A747). Crucially, those missing injecting duration were more likely to 
have positive test results for HCV and HIV (p=0.077 and 0.153 respectively); and this 
difference increased over time, with those missing injecting duration having prevalences 2-3 
times as high in 2012-2013 for all three infections. This indicates a risk of bias in complete 
case analysis of trends. 
Model selection 
The model selection phase, based on the imputed data, did not yield a clear choice in model 
structure in terms of a single best-scoring model, although some variables could be excluded 
with relative certainty (where variables did not appear in any of the best-scoring models). For 
HCV and HBV, number of partners and condom use did not feature in any of the best-scoring 
models, and being born in the UK featured infrequently; these variables were therefore 
omitted and all other variables were retained. This resulted in some “redundant” variables, 
but allowed a more direct comparison between the results for HCV and HBV. For HIV, results 
were even more uncertain, with MSM appearing in all best scoring models but little certainty 
as to which other variables should be included; the only firm conclusion was that very few 
variables could be included without over-fitting to the data.  We selected MSM, age, ever 
received used needles/syringes and condom use for the final model. Detailed tables of the 
model selection results and AIC scores are shown in Appendix B, Supplemental Digital 
Content, http://links.lww.com/QAI/A747. 
Logistic regression results 
Table 2 shows results from multivariable models for HCV, HBV and HIV, based on data from 
the multiple imputation (MI) analysis. In most cases, the univariable complete case, 
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univariable MI and MI multivariable analyses give fairly similar results; we therefore focus on 
the multivariable MI results, but highlight differences between the analyses where they occur. 
Full details of the different models are given in Appendix C, Supplemental Digital Content, 
http://links.lww.com/QAI/A747. 
Differences between regions followed a similar pattern for all three infections, with Southern 
& Eastern England having the highest prevalence and Wales the lowest.  HCV prevalence 
increased over time, although was only borderline significant in 2010-2011 with an odds ratio 
(OR) of 2.47 (95%CI 0.90-6.77) vs. 1999-2003. The pattern is rather different to the 
unadjusted ORs, which had an increase in 2004-2009 then decreasing subsequently; the 
difference in the multivariable results is largely due to adjusting for ever receiving used 
needles/syringes: numbers reporting ever receiving needles/syringes dropped significantly in 
the last two periods, but prevalence of HCV did not fall correspondingly. 
There are some similarities in the temporal pattern for HBV, but prevalence increased more 
markedly in 2004-2009 with an OR of 3.98 (95%CI 1.59-9.97), then decreasing over the next 
two periods. The pattern for HIV was similar, but with an extremely high, albeit uncertain 
increase in 2004-2009 with an OR of 10.01 (95%CI 0.94-106.3) and falling in the subsequent 
two periods. The ORs were attenuated in the multivariable analyses compared to univariable 
results, but all results exhibit substantial uncertainty. 
For each of the three infections prevalence was similar for those aged 25-34 vs. <25, but 
significantly higher in the 35+ age group in univariable analysis; however, there was no 
association after adjusting for injecting duration, which is highly correlated with age. Injecting 
duration was significantly associated with HCV status, with ORs of 6.23 (95%CI 1.27-30.42) 
and 8.53 (95%CI 1.66-43.78) for 2-5 years and 5+ years vs. <2 years respectively. 
Interestingly, despite the high risk of bias identified due to missing data, results for the 
univariable complete case analysis were very similar. The effect of injecting duration on HBV 
followed a similar pattern, but weaker; and results for HIV were similar to HBV, but highly 
uncertain. The different patterns in injecting risk for the three infections were further borne 
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out by results for ever receiving used needles/syringes, which had a strong effect for HCV 
with an OR of 5.57 (95%CI 2.32-13.37) and positive, but non-significant, effect for HBV and 
HIV. Ever using a NSP was found to be protective for HCV (p=0.066) but non-significant for 
HBV. 
Sexuality was found to be an important risk factor for HBV and HIV, with MSMs having a far 
higher prevalence, with ORs of 6.58 (95%CI 2.65-16.34) for HBV and 17.76 (95%CI 4.20-
75.13) for HIV, and non-significant for HCV. Apart from survey period, MSM was the only 
variable to remain significant in the multivariable analysis of HIV. Reported number of 
partners and condom use had little association with any infections, even in univariable 
analyses. We attempted to examine whether the effects of other variables differed according 
to sexuality, i.e. via interactions with MSM, but data were too sparse to do so. 
Previous diagnostic testing for HCV and HIV showed significant positive associations with all 
three infections; as mentioned previously this must be interpreted as a difference in 
underlying risk in those seeking tests and not a causal factor; i.e. testing does not cause an 
increased risk of infection. HBV vaccination showed little association with HCV and HBV 
status, but HIV prevalence was somewhat higher in univariable analyses. Finally, being UK 
born showed no significant associations, although numbers of non-UK born are low, and the 
effect could not be estimated for HIV as there were no infections in this group. 
 
Discussion 
Our findings confirm that BBV infections are a problem among people who inject IPEDs, 
though in part this reflects an overlap with the MSM population. Even so, the prevalence of 
HIV is similar to that among those injecting psychoactive drugs in the UK.32 Though the 
prevalences of HBV and HCV are lower than among those who inject psychoactive 
drugs,33,34 they are most probably higher than the levels in the general population.33,34,35 
AC
CE
PT
ED
Copyright © 201 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.5
11 
Worryingly, even though the prevalence of these three infections might have peaked in the 
second half of the 2000’s, they are currently still higher than during the 1990’s. 
This study has a number of limitations. Firstly, the representativeness of those recruited is 
impossible to measure, as the marginalisation, comparative rarity and illicit nature of injecting 
drug use all impeded the construction of a sampling frame.  Although the survey used an 
established methodology for recruiting PWID;23,24 its robustness for people who inject IPEDs 
is not known and cannot be assessed as information on the nature and size of this group is 
limited.4,14 Secondly, the findings here rely on self-reports; although the reliability of these 
has not been assessed among IPED users, they have been found to be reliable for people 
injecting psychoactive drugs.36,37 The reliability of the sexuality data is a particular concern as 
this was based on the response to a single question about male sexual partners and so the 
extent of sex with men may be under-reported. Responses were occasionally incomplete 
leading to missing data, particularly in relation to age at first injection. This problem was 
partly overcome by the use of MI methods, although it is unclear to what degree bias due to 
systematic missingness may persist; there is no guarantee that the observed relationships 
between variables in the complete data hold for those with missing data. In general, MI and 
complete case analyses were in close agreement; although this does not validate the MI 
approach, it is reassuring that radical differences are not observed. Thirdly, though the 
infection data were based on the testing of biological samples, analysis was limited by the 
small numbers, particularly for HIV. Finally, though the data are drawn from the same 
programme of sero-behavioural surveys there is some methodological variation over time; in 
particular the first three time points drew on a survey of PWID focused on psychoactive drug 
use, whilst the two more recent time periods relate to purposive surveys of IPEDs injectors. 
There may be differences between the risk profiles of those captured in these two survey 
variants, and considering the higher level of sharing, those captured in the general PWID 
survey might have been a higher risk group. Considering these limitations, caution is needed 
when attempting to generalise our findings. 
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The three infections examined here share a common route of transmission through injecting, 
but HBV and HIV are also readily transmitted sexually. The sexual transmission of HCV is 
rare,38 though this may be more common among some groups of MSM, particularly when 
infected with HIV. The results here, although uncertain, reflect this risk pattern: the 
associations of injecting duration and receiving used needles/syringes with HCV infection are 
stronger than those for HBV and HIV, with the latter presumably being diluted by the sexual 
transmission route, which might be assumed relatively high in this population.7,14 This also 
appears to be confirmed by the very strong association of HBV and HIV infection with MSM, 
which was not observed for HCV. If transmission routes for the three infections were 
identical, one would expect the temporal trends to be similar; indeed, there are some 
differences, with a large “spike” in prevalence anti-HBc in 2004-2009 followed by a tailing off, 
which is similar to the pattern of HIV, compared to a relatively flat profile over time for HCV. 
The differences in transmission routes are also borne out by the correlation between 
infections; HIV has no evidence of an association with HCV (although data are sparse) with 
an OR of 2.09 (0.27-16.40) but a strong association with HBV: OR=14.27 (4.68-46.72). HCV 
and HBV have an OR of 7.91 (3.75-16.68); in general, all three infections are likely to be 
correlated due to the shared route of injecting, but for HIV and HBV this is expected to be 
stronger due to these also being sexually transmitted. These theories would be better 
confirmed by modelling all three infections jointly in order to separate out the effect of sexual 
transmission, but due to the paucity of data this was not possible to test formally. 
The extent of these infections and the indication of an increase in prevalence over time for 
HIV and HCV are a concern. Particularly as our data indicate that the uptake of diagnostic 
testing for HIV and HCV among men injecting IPEDs (42.2% and 32.7% respectively in 
2012-13) are much lower than among those injecting psychoactive drugs,33,39 and HBV 
vaccine uptake (44.5% in 2012-13) is poor. Considering the injecting and sexual risks in this 
population, there is a substantial potential for extensive unrecognised spread of BBVs among 
those injecting IPEDs. Though the relative roles of injecting and sexual risks in the 
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transmission of HIV and HBV need further examination, these findings indicate that those 
providing services to PWID need be alert to the infection risks among those who inject 
IPEDs. In particular, they need to be aware that injecting practices associated with IPED use 
differ from those for psychoactive drugs4,7,14 and of the potentially greater sexual risks.4,7,14 
Services working with PWID need to ensure that those injecting IPEDs have access to 
appropriate injecting equipment, targeted harm reduction advice, testing for BBVs, hepatitis 
B vaccinations, sexual health services, and condoms. 
This study reports on the largest sample so far of people who use IPEDs analysed in relation 
to BBV infections and is the first to examine risk over time, however the results need to be 
interpreted with caution. Though further work is needed, the findings indicate that both sexual 
and injection risks are leading to BBV transmission among those injecting IPEDs. The extent 
of IPED use, the characteristics of the users and the drug use profiles of IPED injectors 
attending NSPs in the UK have all changed over time.14,40 However, the role of these factors 
in the changing BBV prevalence requires further investigation. These results also 
demonstrate the need for targeted interventions to address sexual health and drug use risks 
among those injecting IPEDs.   
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Figure 1. Distribution of reported injecting duration and age (at time of survey) over time, 
men injecting IPEDs, England and Wales: 1992-2013 
 
Box and whisker plots with medians, 25th and 75th percentiles and whisker defined as 1.5 
times the inter-quartile range.  
 
Figure 2. Observed prevalence and 95% confidence intervals of anti-HCV, anti-HBc and 
anti-HIV prevalence over time; accounting for imperfect test sensitivity and specificity, men 
injecting IPEDs, England and Wales: 1992-2013 
 
No data are available for anti-HCV prior to 1998 when testing was first introduced into the 
survey. 
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Table 1. Characteristics of participations by men injecting IPEDs over time, England and 
Wales: 1992-2013. P-values indicate significance of changes over time. 
 
 
Men injecting IPEDs participating in 
the main UAM survey of PWID 
UAM Sub-surveys of 
people injecting IPEDs  
 
1992-1997 1998-2003 2004-2009 2010-2011 2012-2013 p-val 
N participations 213 343 129 383 228  
Injecting duration 2 (0-4) 2 (1-5) 3 (1-8) 3 (1-8) 4 (1-10) <0.001 
Age 25 (22-29) 28 (23-32) 29 (24-33) 28 (23-35) 29 (23-35) <0.001 
Never used condom 38% 41% 34% 42% 41% 0.355* 
More than one 
   sexual partner 47% 56% 49% 51% 52% 0.012* 
Area:-       
  London, Southern  
    & Eastern England 
22% 14% 19% 33% 14% 
 
  Midlands (England) 16% 22% 10% 16% 33%  
  Northern England 40% 51% 45% 36% 20%  
  Wales 22% 13% 26% 16% 32% <0.001† 
Ever used NSP  81% 90% 78% 90% 0.001 
Ever received used 
  needle/syringe 
13% 35% 40% 5.8% 4.9% 
<0.001 
HBV vaccination ‡ 21% 46% 34% 44% <0.001 
Tested for HIV 15% 18% 42% 36% 43% <0.001 
Tested for HCV ‡ 7.9% 31% 29% 32% <0.001 
UK-born ‡ 100% 96% 95% 96% 0.81 
MSM 3.3% 3.5% 4.7% 3.4% 6.6% 0.305 
* p-values for condom use and number of partners are based on full categorical variable 
rather than the dichotomised versions presented here. 
† p-value for area based on joint distribution of all areas. 
‡ Data not collected during this time period. 
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Table 2. Multivariable logistic regression results for anti-HCV, anti-HBc and anti-HIV, based on multiple imputation model data, men injecting 
IPEDs, England and Wales: 1992-2013 
 
  
Anti-HCV Anti-HBC Anti-HIV 
  
Number 
observations OR 95% CI p-val OR 95% CI p-val OR 95% CI p-val 
Area 
 
         
London, Southern & Eastern England 278 1 (ref)   1 (ref)      
Midlands (England) 259 0.58 0.22-1.50 0.258 0.37 0.15-0.92 0.032    
Northern England 501 0.61 0.27-1.36 0.224 0.40 0.20-0.80 0.009    
Wales 258 0.19 0.05-0.73 0.015 0.20 0.07-0.55 0.002    
Year 
          
1992-1997 213 NA   0.75 0.22-2.57 0.648   
1998-2003 343 1 (ref)   1 (ref)   1 (ref)*   
2004-2009 129 1.54 0.51-4.59 0.441 3.98 1.59-9.97 0.003 10.01 0.94-106.33 0.056 
2010-2011 383 2.47 0.90-6.77 0.080 1.55 0.66-3.66 0.317 6.46 0.65-64.57 0.112 
2012-2013 228 2.07 0.64-6.71 0.225 0.47 0.13-1.66 0.243 4.12 0.31-54.13 0.281 
Age, years 
          
<25 425 1 (ref)   1 (ref)   1 (ref)   
25-34 588 0.48 0.16-1.44 0.191 0.56 0.26-1.23 0.151 0.57 0.07-4.42 0.590 
35+ 250 1.55 0.52-4.60 0.426 0.64 0.25-1.67 0.364 2.70 0.43-16.87 0.288 
Injecting duration, years 
          
<2 379 1 (ref)   1 (ref)      
2-5 391 6.23 1.27-30.42 0.024 2.12 0.86-5.23 0.102    
>5 297 8.53 1.66-43.78 0.010 2.68 0.99-7.27 0.053    
Ever used NSP 718/862† 0.43 0.18-1.06 0.066 0.70 0.32-1.56 0.389    
Ever received used needle/syringe 227/1272† 5.57 2.32-13.37 <0.001 1.75 0.82-3.73 0.147 3.39 0.71-16.28 0.127 
MSM 53/1296† 1.90 0.58-6.23 0.287 6.58 2.65-16.34 <0.001 17.76 4.20-75.13 <0.001 
Condom use 
          
Always 253       1 (ref)   
Sometimes 487       2.11 0.45-9.93 0.343 
Never 493             0.38 0.03-4.15 0.425 
*1992-97 and 1998-2003 periods combined for HIV;  †Number of “yes” responses / observed response
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Figure 1. Distribution of reported injecting duration and age (at time of survey) over time, 
men injecting IPEDs, England and Wales: 1992-2013 
 
Box and whisker plots with medians, 25th and 75th percentiles and whisker defined as 1.5 
times the inter-quartile range.  
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Figure 2. Observed prevalence and 95% confidence intervals of anti-HCV, anti-HBc and 
anti-HIV prevalence over time; accounting for imperfect test sensitivity and specificity, men 
injecting IPEDs, England and Wales: 1992-2013 
  
No data are available for anti-HCV prior to 1998 when testing was first introduced into the 
survey. 
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